RICHMOND, Calif., Jan. 8, 2018 /PRNewswire/ -- In meetings with investors this week and during a presentation Wednesday at the J.P. Morgan Healthcare Conference in San Francisco, Sangamo Therapeutics, Inc. (NASDAQ: SGMO) Chief Executive Officer, Dr. Sandy Macrae will review the Company's growth and recent progress and outline key priorities and catalysts for the coming year."Last year we made significant progress transitioning Sangamo from its previous research focus to a sustainable, fully integrated company that aims to translate cutting edge science into genomic medicines to transform patients' lives," said Dr. Macrae. "With new management, a clear strategy, the validation of external collaborations, a strengthened balance sheet - and with core values that make the patient the central focus of everything we do - Sangamo is now operating with urgency and efficiency to pursue the vast opportunities presented by our technology platform." Dr. Macrae continued: "We expect a transformative 2018 with key proof-of-concept data for in vivo genome editing and gene therapy clinical programs. Building on last year's foundation, we will also progress our middle pipeline into the clinic, advance our novel delivery platforms and pursue new strategic collaborations combining Sangamo's technology with external expertise and resources for select therapeutic applications." Sangamo will provide 2018 financial guidance when the Company reports fourth quarter and full year 2017 business and financial results later this quarter. Sangamo expects that available cash resources will be sufficient to fund currently planned operations for at least the next two years. Sangamo will be participating in the 36 th Annual J.P. Morgan Healthcare Conference being held in San Francisco from January 8 th to 11 th. Dr. Sandy Macrae, Sangamo's CEO, is scheduled to present on Wednesday, January 10, 2018 at 4:00 p.m. PT. The presentation will be followed by a separate Q&A session starting at 4:30 p.m. PT. A live webcast of Dr. Macrae's presentation and the Q&A session will be accessible through a link on the Investors and Media section of the company's website, under Events and Presentations. About Sangamo TherapeuticsSangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A and gene regulation programs for C9ORF72-linked amyotrophic lateral sclerosis and frontotemporal lobar degeneration; with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease; and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences. For more information about Sangamo, visit the Company's website at www.sangamo.com. Cautionary Statement regarding Forward-Looking Statements This press release contains forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, expected cash and cash equivalents as of the year ended December 31, 2017, the ability of Sangamo to pursue opportunities presented by Sangamo's technology platform, the expectation and timing of key proof-of-concept data for in vivo genome editing and gene therapy clinical programs, the ability of Sangamo to progress its product candidates into the clinic or develop and progress other product candidates in the pipeline, and the ability to pursue new strategic collaborations. Actual results may differ materially from these forward-looking statements due to a number of factors, including differences in the actual level of cash and cash equivalents after completion of the year-end accounting process; uncertainties relating to the ability of Sangamo to execute on its strategic plan in pursuing opportunities with Sangamo's technology platform, the inability to execute on Sangamo's corporate strategy to partner with other pharmaceutical companies or collaborate successfully, and the risk that the data from Sangamo's ongoing clinical trials may not provide proof-of-concept validation or warrant further development and advancement of its product candidates, or that the results of such trials may be delayed. For a more detailed discussion of these and other risks, please see Sangamo's SEC filings, including the risk factors described in its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release. View original content with multimedia: http://www.prnewswire.com/news-releases/sangamo-therapeutics-outlines-2018-key-priorities-and-catalysts-at-jp-morgan-healthcare-conference-300578813.html SOURCE Sangamo Therapeutics, Inc.